My ePortfolio Register   

T cell therapy for ALL

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.12.17
Views: 852

Dr Max Topp - University of Wurzburg, Wurzburg, Germany

Dr Topp speaks with ecancer at the 2017 ASH annual meeting about results from the ZUMA-3 trial looking at KTE-C19, an anti-CD19 chimeric antigen receptor T-cell therapy, in adult patients with relapsed/refractory acute lymphoblastic leukaemia. 

He goes on to say that KTE-C19 has shown promising efficacy in adult patients with relapsed/refractory acute lymphoblastic leukaemia.

The safety profile was generally manageable, though Dr Topp highlights the significant impact of PI3K pretreatment on patient outcomes, and additional approaches to improve the risk profile are being explored.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.


Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence